7.240USD+2.26%Mkt Cap: 369.02M USDP/E: 15.10Last update: 2026-05-26
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of n…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap369.02M USD
Enterprise Value273.25M USD
Revenue (TTM)227.18M USD
Gross Profit170.21M USD
Net Income (TTM)31.11M USD
Revenue/Share4.514 USD
Last Price7.240 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees179
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)15.10
P/E (Forward)20.14
PEG—
EV/EBITDA6.93
EV/Revenue1.20
P/S1.58
P/B2.79
EPS (TTM)0.48
EPS (Forward)0.35
52W Range
3.03086% of range7.900
52W High7.900 USD
52W Low3.030 USD
Profitability
Gross Margin74.53%
Oper. Margin-8.54%
EBITDA Margin17.35%
Profit Margin13.62%
ROE23.87%
ROA14.38%
Growth
Revenue Growth-2.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF41.80M USD
CapEx (TTM)71.00K USD
FCF Margin19.41%
FCF Yield11.95%
Net Debt-85.59M USD
Net Debt/EBITDA-2.17
Balance Sheet
Debt/Equity0.22
Current Ratio2.38
Quick Ratio2.14
Book Value/Sh2.524 USD
Cash/Share1.995 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Target (Mean)5.000 USD
Target Range5.000 USD – 5.000 USD
# Analysts1
Ownership
Shares Out.50.90M
Float39.09M
Insiders15.38%
Institutions77.53%
Short Interest
Short Ratio15.2d
Short % Float9.47%
Short % Out.8.07%
Shares Short4.11M
Short (prev mo.)3.94M
Technical
SMA 506.974 (+3.8%)
SMA 2005.913 (+22.4%)
Beta1.23
S&P 52W Chg28.31%
Avg Vol (30d)268.53K
Avg Vol (10d)296.78K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—